Covered recipient · General Payments record
ANNA DANIELLE CRAMER
Physician Assistants & Advanced Practice Nursing Providers Nurse Practitioner Family
General Payments · PY2021–2024
$13,933.38
- Reported across 105 records
- CMS publication 2026-01-23
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How these totals are calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
PY2024 · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $1,755.22 | 15 |
By paying entity
PY2024 · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| ABBVIE INC. | $540.13 | 5 |
| Gilead Sciences, Inc. | $270.78 | 2 |
| Ferring Pharmaceuticals Inc. | $260.54 | 2 |
| Janssen Biotech, Inc. | $136.44 | 1 |
| Janssen Scientific Affairs, LLC | $117.78 | 1 |
| Insulet Corporation | $113.93 | 1 |
| Lilly USA, LLC | $111.58 | 1 |
| Takeda Pharmaceuticals U.S.A., Inc. | $104.20 | 1 |
| PFIZER INC. | $99.84 | 1 |
By program year
All program years on this page · sorted by year
Payment records · PY2024 (15)
Sorted by paying entity, then date · as published by CMS
| Paying entity | Amount | Date | Nature of payment | Dispute status | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|
| ABBVIE INC. | $105.71 | 02/29/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1106963090 | CMS |
| ABBVIE INC. | $99.42 | 05/02/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1106963092 | CMS |
| ABBVIE INC. | $108.26 | 05/30/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1106963094 | CMS |
| ABBVIE INC. | $107.22 | 07/24/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1106963096 | CMS |
| ABBVIE INC. | $119.52 | 08/15/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1106963098 | CMS |
| Ferring Pharmaceuticals Inc. | $112.16 | 01/25/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1137525950 | CMS |
| Ferring Pharmaceuticals Inc. | $148.38 | 04/18/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1137525955 | CMS |
| Gilead Sciences, Inc. | $121.60 | 05/01/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1133695120 | CMS |
| Gilead Sciences, Inc. | $149.18 | 07/18/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1133695122 | CMS |
| Insulet Corporation | $113.93 | 10/03/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1116815711 | CMS |
| Janssen Biotech, Inc. | $136.44 | 09/25/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1078282517 | CMS |
| Janssen Scientific Affairs, LLC | $117.78 | 09/12/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1078844529 | CMS |
| Lilly USA, LLC | $111.58 | 05/17/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1135448353 | CMS |
| PFIZER INC. | $99.84 | 05/15/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1131794703 | CMS |
| Takeda Pharmaceuticals U.S.A., Inc. | $104.20 | 07/10/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1137729564 | CMS |
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-01-23
- Program years on this page
- 2021, 2022, 2023, 2024
- Generated from
- OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.